Judge Cites Opioid ‘Menace,’ Awards Oklahoma $572M In Landmark Case
The state judge ruled that drugmaker Johnson & Johnson contributed to the opioid epidemic that has claimed the lives of 6,000 Oklahomans.
Drugs
721 - 740 of 1,288 Results
-
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Readers And Tweeters Take Dialysis Providers To Task: Nowhere But In The USA
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
KHNs What The Health?: All About Medicare
Before Medicare for All, there was just Medicare, the federal program that provides insurance to 60 million Americans. This week, KHNs Julie Rovner talks to Tricia Neuman of the Kaiser Family Foundation about how Medicare works and whom it serves. Then, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Kimberly Leonard of the Washington Examiner join Rovner to talk about some current Medicare issues being debated in Washington, D.C.
-
Shopping Abroad For Cheaper Medication? Heres What You Need To Know
Americans routinely skirt federal law by crossing into Canada and Mexico or tapping online pharmacies abroad to purchase prescription medications at a fraction of the price they would pay at home. Is it safe? Not necessarily. Heres some advice.
-
MDMA, Or Ecstasy, Shows Promise As A PTSD Treatment
MDMA, the psychoactive ingredient in the club drug known as molly or ecstasy, is being tested in combination with therapy as a treatment for severe trauma.
-
Among Hurdles For Those With Opioid Addictions: Getting The Drug To Treat It
It can be difficult to get a prescription for buprenorphine, one of the gold standards for treating opioid use disorder. And not all pharmacies stock the drug.
-
KHNs What The Health?: We Answer Your Questions
You asked about drug prices, the Cadillac tax on generous insurance plans and why Americans dont know that most other countries also have combination public-private insurance systems. This week, Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico and Caitlin Owens of Axios join KHNs Julie Rovner to answer those questions.
-
Doctors Can Change Opioid Prescribing Habits, But Progress Comes In Small Doses
Research out Wednesday indicates that guidelines are making strides in cutting back the number of pain pills doctors offer after specific types of surgeries.
By Julie Appleby and Elizabeth Lucas -
KHNs What The Health?: Gun Violence And The Politics Of Public Health
The recent tragic mass shootings have refocused efforts to treat gun violence as a public health issue rather than strictly a law enforcement problem. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Agnes Carey of Kaiser Health News join KHNs Julie Rovner to discuss this, plus the health implications of the budget deal passed by Congress and signed by President Donald Trump, as well as reaction from Canada to a proposal to allow broader imports of its prescription drugs. Plus, for extra credit, the panelists recommend their favorite health stories of the week.
-
Price Of Snakebite Drug Is Sky High, But New Competitor Unlikely To Lower Costs
The drug CroFab, which has been on the market since 2000, now faces competition from a drug called Anavip. But both are expensive.
-
Federal Experts Advice On HPV Vaccine Could Leave Adults Confused
A federal advisory panel says people between ages 27 and 45 may benefit from the vaccine to fight the human papillomavirus. But some public health advocates worry that the advice doesnt provide doctors and patients clear guidance about who in this large age group are good candidates for the vaccine.
-
Drugmakers Master Rolling Out Their Own Generics To Stifle Competition
Known as authorized generics, in-house spinoffs of brand-name drugs quietly undermine the competition.
By Jay Hancock and Sydney Lupkin -
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you dont have to.
-
Infusion Treatments Needed or Not Can Deplete Patients Wallets
When it comes to physician-administered infusion drugs, doctors sometimes have a financial reason for their choice and patients often arent aware of cheaper options.
-
Podcast
KHNs What The Health?: Deciphering The Democrats Health Debate
Health care was a major topic at the Democratic presidential candidate debates in Detroit on Tuesday and Wednesday, but the focus on plan minutiae may have left viewers more confused than edified. Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Caitlin Owens of Axios join KHNs Julie Rovner to discuss the points made by the candidates plus a series of Trump administration health initiatives on drug prices and hospital shopping.
-
California Bill Would Fight Deals That Delay Generic Drugs
As California Attorney General Xavier Becerra cracks down on pharmaceutical companies he said paid competitors to delay generic versions of their drugs, hes also pushing for legislation that would give his department tools to catch more of them. Its the first of its kind in the nation.
-
Trump Administration Open For Business On Drug Imports From Canada
HHS secretary announces a preliminary plan Wednesday to allow Americans to import certain lower-cost drugs from Canada. Manufacturers were quick to criticize the plan, saying it does not guarantee the safety of drugs coming into the country.
-
Trump Administration Moves To Make Health Care Costs More Transparent
The proposed rules would require hospitals to provide far more detail about the actual prices they charge insurers for patients care.
-
New Protocol For HIV Prevention Drug Reduces The Number Of Pills Required
Health officials and AIDS advocates in San Francisco have endorsed a new regimen for PrEP medication: to be taken only immediately before and after sex, thus reducing cost and potential side effects. The standard regimen is one pill a day for an open-ended period.
By David Tuller